February 09, 2010 04:00 ET

IDBS Biomarker Discovery and Validation Solution Helps Lung Genomics Research Consortium Manage and Analyze Phenotypic and Genomic Data

GUILDFORD, UK and BURLINGTON, MA--(Marketwire - February 9, 2010) - IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that its Biomarker Discovery and Validation Solution will be a key component in an $11 million National Heart, Lung and Blood Institute (NHLBI) award to create a molecular roadmap for chronic lung diseases. The project's infrastructure will be developed and hosted by the new Center for Cancer Computational Biology (CCCB) at Dana-Farber Cancer Institute. The award was given to the Lung Genomics Research Consortium (LGRC), led by National Jewish Health and also includes Dana-Farber Cancer Institute, Boston University, University of Colorado Denver, and University of Pittsburgh.

The multi-center LGRC will use advanced genetic and molecular tools to characterize and better understand chronic obstructive pulmonary disease and pulmonary fibrosis, then share its discoveries with researchers around the world in a web-accessible data warehouse. Combining genetic, epigenetic, transcriptional, and phenotypic data will provide an unprecedented window into these diseases, improving diagnosis and future personalized treatments. Data will be generated from a biorepository of almost 1,300 well characterized tissue samples from patients with chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and other chronic lung diseases.

The IDBS Biomarker Discovery and Validation Solution, based on the InforSense and E-WorkBook Suites, will provide the infrastructure to manage, analyze and visualize the phenotypic and genomic data generated in the project. IDBS will also provide ClinicalSense and VisualSense to deliver web interfaces, enabling researchers to leverage this new data source.

"The LGRC project aims to produce an invaluable resource to enable better characterization and treatment of these deadly and poorly served lung diseases. We created the Center for Cancer Computational Biology specifically to work on this type of research," said Professor John Quackenbush, Director of the Center for Cancer Computational Biology at Dana-Farber Cancer Institute. "We will be using the IDBS solution to help manage and analyze the phenotypic and genomic data generated as part of the project."

"We are delighted to be part of such a ground breaking research project and to be extending our relationship with Dana-Farber and the CCCB," said Neil Kipling, founder and CEO of IDBS. "Translational and biomarker research continues to be a primary focus at IDBS, with extensive investment being made in developing the InforSense and E-WorkBook Suites and applying our other world leading products in this field."

About IDBS

IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.

IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China. Find out more at

Contact Information

  • Media enquiries
    Danielle Guinebertiere
    Communications Director
    Tel: +1 908 429 2933
    Email: Email Contact